Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 23, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - November 23, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/23/14 - Canada : Aeterna Zentaris Adds Hollings Cancer Center to Multi-National Phase 3 Trial in Endometrial Cancer [TendersInfo (India)]
Aeterna Zentaris Inc. today announced the opening of a new clinical site at the Hollings Cancer Center of the Medical University of South Carolina in Charleston, South Carolina, for the Company's ongoing multinational, pivotal ZoptEC Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. Also, we are very pleased to be wo
11/23/14 - FDA Grants Orphan Drug Designation to Astellas for Isavuconazole for the Treatment of Invasive Candidiasis
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Astellas announced that the U.S. Food and Drug Administration has granted orphan drug designation to isavuconazole for the treatment of invasive candidiasis. An FDA orphan drug designation provides several benefits to the sponsor including a seven-year period of market exclusi
11/23/14 - FDA Issues Complete Response Letter for Aeterna Zentaris' Macrilen? NDA in Adult Growth Hormone Deficiency
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Aeterna Zentaris Inc. announced that the Company has received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application for Macrilen?, a novel orally-active ghrelin agonist, for use in evaluating adult growth hormone deficiency.
11/23/14 - Ralph Nader: Big PharmaCrony Capitalism Out Of Control OpEd [Albany Tribune (OR)]
Two recent news items about the voracious drug industry should call for a supine Congress to arouse itself and initiate investigations about the pay-or-die drug prices that are far too common. The first item a page one story in the New York Times was about the Cystic Fibrosis Foundation, which fifteen years ago invested $150 million in the bi
11/23/14 - Ralph Nader: Big PharmaCrony Capitalism Out Of Control OpEd [Eurasia Review]
Two recent news items about the voracious drug industry should call for a supine Congress to arouse itself and initiate investigations about the pay-or-die drug prices that are far too common. The first item a page one story in the New York Times was about the Cystic Fibrosis Foundation, which fifteen years ago invested $150 million in the bi
11/23/14 - Researchers at National Heart Lung and Blood Institute Report New Data on Clinical Trials and Studies (Reconciling the Divergent Findings from...
For more information on this research see: Reconciling the Divergent Findings from Clinical Trials and Observational Studies of Menopausal Hormone Therapy for Prevention of Coronary Heart Disease. Seminars in Reproductive Medicine, 2014; 32: 426-432. Seminars in Reproductive Medicine can be contacted at: Thieme Medical Publ Inc, 333 Seventh Ave, Ne
11/23/14 - Spain : PharmaMar results for antitumoral compounds and their mechanism of action at EORTC-NCIAACR emphasize an innovative pipeline of targeted... [TendersInfo (India)]
Spain: PharmaMar results for antitumoral compounds and their mechanism of action at EORTC-NCIAACR emphasize an innovative pipeline of targeted therapies. Zeltia announces that its pharmaceutical company PharmaMar, will present various abstracts at the annual symposium on Molecular Targets and Cancer Therapeutics of the European Organisation for...
11/23/14 - United States : PARTNERSHIP with Synergy Partners signed by ABLS to advance biopharmaceutical innovations from US [TendersInfo (India)]
Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise mutually possessed between Allied Minds and Bristol-Myers Squibb Company, declared that it formed a strategic partnership with Synergy Partners R&D Solutions, LLC. Their team of scientists presents expertise in areas for example disease biology, medicinal chemistry, process chemistry
11/22/14 - "Methods of Inhibiting Tumor Growth by Antagonizing Il-6 Receptor" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventor ZHANG, LI, filed on July 11, 2014, was made available online on November 6, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Regeneron Pharmaceuticals, In
11/22/14 - Colby Pharmaceutical Company - Product Pipeline Review - 2014 - New Market Report [ClickPress (UK)]
Global Markets Direct's,' Colby Pharmaceutical Company- Product Pipeline Review- 2014', provides an overview of the Colby Pharmaceutical Company's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Colby Pharmaceutical Company's, complete with...
11/22/14 - Dr. Reddy's launches OTC Fexofenadine Hydrochloride 60 g and Pseudoephedrine Hydrochloride 120mg extended-release tablets [EMBIN (Emerging Markets Business Information News]
Dr. Reddy's Laboratories has launched its over-the-counter Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg/ 120 mg, a bioequivalent generic version of Allegra-D? 12 Hour Allergy& Congestion, in the U.S. market on November 18, 2014. Dr. Reddy's Laboratories is an integrated global pharmaceutical compan
11/22/14 - Flagler company inks Chinese export deal [EMBIN (Emerging Markets Business Information News]
Nature's Nurse International, a Flagler Beach company, announced that it has entered into a partnership with Chinese pharmaceutical company Sinopharm, which has agreed to begin marketing its products in China beginning next month. The company's staff is made up of 11 independent contractors in Flagler Beach and Atlanta as well as three in Fiji, sai
11/22/14 - France : DLA Piper represents Neothetics in initial public offering [TendersInfo (India)]
DLA Piper advised Neothetics, Inc., a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, in the pricing of its initial public offering of 4,650,000 shares of its common stock at a public offering price of $14.00 per share. The San Diego- based DLA Piper team representing Neothetics was led by partners
11/22/14 - Generic drug prices skyrocket in past year [Chicago Tribune]
The 44- year-old piano tuner and guitar instructor from Elgin, who has health insurance, used to pay $20 for a three-month supply of his generic epilepsy drug as a member of Walgreen's Prescription Savings Club. But in the past year, the price of many generics is disconcertingly moving in the wrong direction, drawing the attention of Congress and p
11/22/14 - Global pharmaceutical firm joins Rwanda in cancer fight [New Times, The (Rwanda)]
Rwanda could soon be one of the first countries in Africa to venture into clinical trial tests and research for cancer and other diagnostic diseases. This follows an exploratory visit by Robert Mulroy, the CEO of Merrimack Pharmaceuticals, a biopharmaceutical company involved in developing and preparing innovative medicines for the treatment of ser
11/22/14 - Highland Therapeutics receives second notice of allowance for patent on Lead product [EMBIN (Emerging Markets Business Information News]
Highland Therapeutics, a pharmaceutical company, announced that the US Patent and Trademark Office has issued a Notice of Allowance for a patent application for HLD-200, a novel formulation of methylphenidate designed to be taken once-daily in the evening with the objective of controlling symptoms of ADHD immediately upon awakening and throughout t
11/22/14 - Mental patients are being denied essential drugs [Ghana News Agency]
Abura, Nov. 21, GNA- More than 300 mental patients visiting Abura Dunkwa Psychiatric Hospital cannot access essential medicines, because they are either not available or expensive. Mr Turkson, who is the Abura-Aseibu-Kwamankese District Mental Health Officer, told Ghana News Agency on the sidelines of a community durbar organised by BasicNeeds Ghan
11/22/14 - OncoMed Offers Data from Demcizumab; Celgene Receives Positive CHMP Opinion For OTEZLA
Below is a look at some of the headlines for companies that made news in the healthcare sector on November 21, 2014.{ nfg} OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics which target cancer stem cells, or tumor-initiating cells, presented data in two posters highlighting the company's translational research an
11/22/14 - SHAREHOLDER ALERT: Investigation on Behalf of Arrowhead Research Corporation Investors Announced by Law Offices of Howard G. Smith
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Arrowhead Research Corporation. If you purchased Arrowhead shares, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to
11/22/14 - Soaring generic drug prices draw Senate scrutiny [EMBIN (Emerging Markets Business Information News]
A Senate panel met Thursday to scrutinize the recent, unexpected trend among generic medicines, which usually cost 30 to 80 percent less than their branded counterparts. Bernie Sanders, who chairs the Senate Subcommittee on Primary Health and Aging. Sanders introduced a bill that would require generic drugmakers to pay rebates to the federal Medica
11/22/14 - Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment
Sprout Pharmaceuticals today announced positive preliminary results from a Phase 1 driving study, which demonstrate that women treated with flibanserin up to 200 mg at bedtime had no next-day impairment of driving ability. The data were presented at the 20 th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America in Miami.
11/22/14 - Tekmira Provides Key Highlights of Analyst and Investor Day in New York
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today an update from the Company's Analyst and Investor Day, which took place on November 21 in New York City. The Company announced its first regulatory filing, in the form of a Clinical Trial Application filed with Health Canada, to support its
11/22/14 - Testosterone treatment: Fountain of youth or heart attack risk? [The Indianapolis Star]
Nov. 22 It's almost predictable. First came the drug company ads aimed at older men. Feeling tired, irritable, lost your sex drive?
11/22/14 - United States : FDA approves extended-release, single-entity hydrocodone product with abuse-deterrent properties [TendersInfo (India)]
Hysingla ER has approved labeling describing the product s abuse-deterrent properties consistentwith the FDA s 2013 draft guidance for industry, Abuse-Deterrent Opioids Evaluation and Labeling. The FDA has determined that the physical and chemical properties of Hysingla ER are expected to make abuse by these routes difficult. While the science of a
11/21/14 - "Borosilicate Glass Having Improved Hydrolytic Resistance for Preferred Use in the Pharmaceutical Sector" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Health& Medicine Week A patent application by the inventors Tratzky, Stephan; Kass, Christof; Eichholz, Rainer; Nass, Peter, filed on April 28, 2014, was made available online on November 6, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent applicatio
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Newest and Most Current Medications in the Treatment of Diabetes
This lesson is supported by:
RxSchool
HIV & AIDS Testing & Reporting Guidelines
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415